Because IL-6 is implicated in the pathological conditions and severity of COVID-19 [16,17], we decided to perform a literature search to find an approved drug that would inhibit the expression/secretion of this interleukin and the number of monocytes and macrophages infiltrating the lungs. The gene discussed is IL6; the disease is COVID-19.